Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA known ✓ | P17252 | 3/20 | 0.39 |
| ▸ | PRKCE known ✓ | Q02156 | 1/20 | 0.37 |
| ▸ | PRKCQ known ✓ | Q04759 | 1/20 | 0.37 |
| ▸ | PRKCD known ✓ | Q05655 | 1/20 | 0.37 |
| ▸ | DGKA | P23743 | 1/20 | 0.49 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.43 |
| ▸ | PAM | P19021 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18209372 | 1.00 | DGKA (0.49) | DGKADNM1PRKCAPAMKDM4E | |
| SCHEMBL1044584 | 0.99 | DGKA (0.50) | DGKADNM1PRKCAPAMKDM4E | |
| Hydrochloric Acid SCHEMBL421821 | 0.93 | MGLL (0.50) | DGKAPRKCAALDH1A1MGLLEPHX2 | |
| Hydrochloric Acid SCHEMBL1047267 | 0.93 | MGLL (0.50) | DGKAPRKCAALDH1A1MGLLEPHX2 | |
| SCHEMBL747314 | 0.92 | MGLL (0.51) | DGKAPRKCAALDH1A1MGLLEPHX2 | |
| SCHEMBL441411 | 0.92 | MGLL (0.51) | DGKAPRKCAALDH1A1MGLLEPHX2 | |
| Water SCHEMBL6549699 | 0.91 | MGLL (0.50) | DGKAPRKCAALDH1A1MGLLEPHX2 | |
| Hydrochloric Acid SCHEMBL21293922 | 0.89 | DGKA (0.50) | DGKADNM1PRKCAPAMLMNA | |
| Hydrochloric Acid SCHEMBL21328518 | 0.89 | DGKA (0.50) | DGKADNM1PRKCAPAMLMNA | |
| SCHEMBL22400859 | 0.87 | DGKA (0.51) | DGKADNM1PRKCAPAMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035723-A1 | Treatment of Pancreatic Cancer | SYNCORE BIOTECHNOLOGY CO., LTD. (TW) | 2023-02-02 | — | — | US | claimed |
| US-20220313608-A1 | TREATMENT OF BREAST CANCER | SYNCORE BIOTECHNOLOGY CO., LTD. (TW) | 2022-10-06 | — | — | US | claimed |
| US-11173119-B2 | Nanolipogel vehicles for controlled delivery of different pharmaceutical agents | YALE UNIVERSITY (US) | 2021-11-16 | — | — | US | claimed |
| EP-3397244-B1 | TREATMENT OF BREAST CANCER USING A COMBINATION OF A CATIONIC LIPOSOMAL FORMULATION OF TAXANE, A NON-LIPOSOMAL FORMULATION OF TAXANE AND A FURTHER ACTIVE AGENT | SYNCORE BIOTECHNOLOGY CO LTD (TW) | 2021-10-06 | — | — | EP | claimed |
| CN-108883068-B | Breast cancer treatment | 杏国新药股份有限公司 | 2021-09-10 | — | — | CN | claimed |
| US-10709664-B2 | Nanolipogel comprising a polymeric matrix and a lipid shell | YALE UNIVERSITY (US) | 2020-07-14 | — | — | US | claimed |
| US-20200179283-A1 | Vehicles For Controlled Delivery of Different Pharmaceutical Agents | NATIONAL SCIENCE FOUNDATION | 2020-06-11 | — | — | US | claimed |
| US-20190209474-A1 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES AND DISORDERS | MODULATE THERAPEUTICS INC (CA) | 2019-07-11 | — | — | US | claimed |
| EP-2836234-B1 | VEHICLES FOR CONTROLLED DELIVERY OF DIFFERENT PHARMACEUTICAL AGENTS | UNIV YALE (US) | 2019-06-12 | — | — | EP | claimed |
| US-10195144-B2 | Methods of treating inflammatory and autoimmune diseases and disorders | YALE UNIVERSITY (US) | 2019-02-05 | — | — | US | claimed |
| US-20190015332-A1 | TREATMENT OF BREAST CANCER | SynCore Biotechnology Co. Ltd. (TW) | 2019-01-17 | — | — | US | claimed |
| US-9707204-B2 | Treatment of breast cancer | SYNCORE BIOTECHNOLOGY CO., LTD. (TW) | 2017-07-18 | — | — | US | claimed |
| US-9610250-B2 | Nanolipogel vehicles for controlled delivery of different pharmaceutical agents | YALE UNIVERSITY (US) | 2017-04-04 | — | — | US | claimed |
| US-9603800-B2 | Methods of treating inflammatory and autoimmune diseases and disorders using nanolipogels | YALE UNIVERSITY (US) | 2017-03-28 | — | — | US | claimed |
| US-20160081929-A1 | Method of Administering a Cationic Liposomal Preparation | MEDIGENE AG (DE) | 2016-03-24 | — | — | US | claimed |
| US-9233094-B2 | Method of administering a cationic liposomal preparation | MEDIGENE AG (DE) | 2016-01-12 | — | — | US | claimed |
| US-20150359778-A1 | Treatment of Triple Receptor Negative Breast Cancer | SYNCORE BIOTECHNOLOGY CO., LTD (TW) | 2015-12-17 | — | — | US | claimed |
| US-9144563-B2 | Treatment of triple receptor negative breast cancer | MEDIGENE AG (DE) | 2015-09-29 | — | — | US | claimed |
| US-20150118318-A1 | Methods of Treating Inflammatory and Autoimmune Diseases and Disorders | YALE UNIVERSITY (US) | 2015-04-30 | — | — | US | claimed |
| US-20150064265-A1 | Vehicles for Controlled Delivery of Different Pharmaceutical Agents | YALE UNIVERSITY | 2015-03-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150064265-A1 | Vehicles for Controlled Delivery of Different Pharmaceutical Agents | CETP, HDLBP, ABCG2 | PRKCA 2469/4885PRKCE 1903/4885PRKCQ 2470/4885 |
| US-11173119-B2 | Nanolipogel vehicles for controlled delivery of different pharmaceutical agents | LIPA, ABCF1, ABCG2 | PRKCA 2266/4885PRKCE 1528/4885PRKCQ 2334/4885 |
| US-20190209474-A1 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES AND DISORDERS | UACA, HLA-DRB1, TNF | PRKCA 3750/4885PRKCE 3367/4885PRKCQ 3287/4885 |
| US-20200179283-A1 | Vehicles For Controlled Delivery of Different Pharmaceutical Agents | CETP, HDLBP, ABCG2 | PRKCA 2469/4885PRKCE 1903/4885PRKCQ 2470/4885 |
| US-10709664-B2 | Nanolipogel comprising a polymeric matrix and a lipid shell | LIPA, CD44, ABCB4 | PRKCA 3671/4885PRKCE 2775/4885PRKCQ 3136/4885 |
| US-20150118318-A1 | Methods of Treating Inflammatory and Autoimmune Diseases and Disorders | UACA, HLA-DRB1, TNF | PRKCA 3750/4885PRKCE 3367/4885PRKCQ 3287/4885 |
| US-10195144-B2 | Methods of treating inflammatory and autoimmune diseases and disorders | UACA, HLA-DRB1, LIPA | PRKCA 3709/4885PRKCE 3297/4885PRKCQ 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.